Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
Nenocorilant features among the latest industry projects newly into phase 1.
A deal with Jacobio is worth $100m up front.
The private ADC company is being wound down.
